Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly out-of-pocket price cap, which is set by law.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and currently trading at $756.99. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas. See why LLY stock is a Buy.

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This pattern is drawn when a stock’s 50-day moving average breaks below its 200-day moving average. A Death Cross typically forecasts another 4-6 months of selling pressure for a stock.

And although shares fell 35% from peak-to-trough, it became apparent that those who seek these weight-loss drugs also tend to have sleep apnea and need ongoing treatment from ResMed's products. Since this bottoming out,

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks on Jim Cramer’s radar.

U.S. lumber market could see higher prices within a month: analyst The U.S. construction industry may face higher lumber prices within a month if President Donald Trump follows through with his threat of tariffs on Canada this weekend.

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock

President Donald Trump’s Medicare agency is seeking to bring more transparency to the US government’s drug price negotiation program, indicating plans to move forward with the second round of the program initiated by the Biden administration.

Europe 'Must Fix' Weaknesses to Compete, EU's Von der Leyen Says EU nations must work together quickly to help the bloc compete against global economic powerhouses like China and the U.S., European Commission President Ursula von der Leyen said.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two